NICE Recommends Grifols’ Tavlesse for Chronic Autoimmune Condition

The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) prescribe Grifols’ Tavlesse (fostamatinib) to adult patients with chronic immune thrombocytopenia (ITP) who are resistant to other treatments.

Chronic ITP is an autoimmune condition characterized by low levels of blood platelets.

Specifically, the NICE recommendation is for chronic ITP patients who previously received a thrombopoietin receptor agonist (TPO-RA) or for whom a TPO-RA is unsuitable.

NICE noted fostamatinib was effective compared with a placebo, but that there is currently no clinical trial evidence directly comparing fostamatinib with rituximab or mycophenolate. The agency’s recommendation was based on cost-effectiveness estimates of Tavlesse compared with rituximab.